ArticleAmerican journal of cancer research2025
Prognostic nomogram for advanced epithelial ovarian cancer in the era of homologous recombination testing and PARP inhibitor therapy.
Article in American journal of cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Homologous recombination (HR) status plays a critical role in selecting advanced epithelial ovarian cancer (EOC) patients for poly (ADP-ribose) polymerase inhibitor (PARPi) therapy. This study aimed to develop a novel nomogram to predict prognosis in these patients in the era of precision medicine. We conducted a single-institute retrospective analysis on patients diagnosed with advanced EOC between January 2021 and January 2024. Clinicopathological factors, HR status, and PARPi use were evaluated for their association with survival outcomes. Multivariate Cox regression analysis identified independent predictors of progression-free survival (PFS), and a nomogram was constructed and validated using bootstrap resampling. Among 128 patients, PARPi maintenance therapy was administered after front-line chemotherapy to 43 patients as indicated. Multivariate analysis identified optimal surgery [hazard ratio 0.47, 95% confidence interval (CI) 0.27-0.83], CA-125 > 10.7 U/mL after front-line chemotherapy [hazard ratio 3.41, 95% CI 1.85-6.31], neoadjuvant chemotherapy [hazard ratio 2.55, 95% CI 1.32-4.91], and PARPi use [hazard ratio 0.22, 95% CI 0.12-0.42] as independent predictors of PFS. Patients with all favorable factors had a predicted 3-year PFS of 100%, compared to 0% for those with none. The nomogram demonstrated strong predictive accuracy, with a concordance index of 0.78, and calibration plots showed excellent agreement. Internal validation confirmed the reliability of the nomogram. Our findings indicate that HR-deficient patients who respond well to upfront optimal debulking surgery and chemotherapy (indicated by a post-treatment CA125 level below 10.7 U/mL) may experience excellent PFS when followed by PARPi maintenance. Our nomogram provides a dependable tool for personalized prognosis assessment, enabling clinicians to optimize treatment strategies in the era of precision medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.